LINE
Lineage, Inc. Common StockNASDAQREAL ESTATEREIT - INDUSTRIAL
Key Statistics
Market Cap
$9.10B
P/E Ratio
—
EPS
$-0.43
Beta
—
52W High
$55.57
52W Low
$30.81
50-Day MA
$36.92
200-Day MA
$38.31
Dividend Yield
5.91%
Profit Margin
-1.87%
Forward P/E
769.23
PEG Ratio
—
About Lineage, Inc. Common Stock
Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm focused on regenerative medicine, specifically developing cutting-edge cell therapy solutions for treating debilitating conditions, including ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust network of strategic collaborations, Lineage is poised to transform patient care through innovative therapeutic interventions. The company's commitment to advancing its diverse product pipeline and expediting clinical research positions it as an attractive investment opportunity for institutional investors seeking to engage in the forefront of healthcare advancements.
Fundamentals
| Revenue (TTM) | $5.36B |
| Gross Profit (TTM) | $1.72B |
| EBITDA | $1.14B |
| Operating Margin | 5.17% |
| Return on Equity | -1.19% |
| Return on Assets | 0.81% |
| Revenue/Share (TTM) | $23.49 |
| Book Value | $36.33 |
| Price-to-Book | 1.00 |
| Price-to-Sales (TTM) | 1.70 |
| EV/Revenue | 3.027 |
| EV/EBITDA | 14.59 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -0.20% |
| Shares Outstanding | $227.08M |
| Float | $57.17M |
| % Insiders | 68.71% |
| % Institutions | 33.44% |
Historical Volatility
HV 10-Day
31.58%
HV 20-Day
43.45%
HV 30-Day
42.55%
HV 60-Day
43.38%
HV Rank
71.8%
Volatility is currently contracting
Analyst Ratings
Consensus ($41.37 target)
1
Strong Buy4
Buy12
Hold3
Strong SellData last updated: 4/17/2026